© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
December 17, 2021
Fuad El Rassi talks about the Grady Comprehensive Sickle Cell center, the COVID-19 vaccine, and the data he presented at ASH.
December 14, 2021
The enrollment distribution was consistent by ethnicity over the course of 18 years, with no change in diversity over time despite there being an increase in the UK in the minority population.
Of the SCD patients who contracted COVID-19, 49% of them visited the Grady Comprehensive Sickle Cell center because of a vaso-occlusive event.
Data show patients with sickle cell disease identified by distinct cognitive profile should have neurorehabilitation tailored to each unique profile.
After 2 months of voxelotor treatment, all patients with sickle cell anemia perceived global improvement, but peak VO2 did not change in 8 of 9 patients.
Data show most patients (60.3%) with sickle cell disease achieved a Hb increase of >1 g/dL during the follow-up period.
Patients with SCD were not at an increased risk of death or disease complications.
High dose vitamin D supplementation has been linked to fewer pain days and higher physical activity scores for patients with chronic pain.
New ASH 2021 data for the stem cell transplant therapy suggest it has a durable and safe benefit for adults with severe disease.
Investigators added improvements were needed regarding access to complete diagnostic evaluation among Black patients, citing disparities in care.
Jennifer Green, MD: Outcomes, Impact of SGLT2i, GLP-1 RA Combination Therapy
Joshua J. Joseph, MD: Managing CV Risk Factors in Patients with Type 2 Diabetes
Antirituximab Antibodies Detected in Patients with Pemphigus